Menopause Hormone Therapy: Pill, Patch, Gel and Vaginal Routes
Menopausal hormone therapy can be given as a pill, patch, gel or vaginal treatment. How does each route affect clot and stroke risk, who suits which, and why does a woman with a uterus need a second hormone?
The benefit and risk of menopausal hormone therapy depend not only on the medicine itself but on the route by which it enters the body. Estrogen taken as a pill passes through the liver first and affects the blood's clotting balance. Estrogen absorbed through the skin (patch, gel, spray) bypasses the liver and enters the bloodstream directly, without that effect. Vaginal estrogen acts only on the local tissue. This article explains the difference between the three routes, which one is preferred in which situation, and why a woman with a uterus needs a protective second hormone. For the general framework see our menopause treatment page, and for the question of timing see when to start hormone therapy.
How Do the Three Routes Work?
Pill (oral) route: Estrogen taken by mouth is absorbed from the gut, reaches the liver and is largely altered there. Because of this "first pass through the liver," a higher amount of hormone is needed for the same effect. During this step the liver also makes more clotting proteins, blood fats (triglycerides) and hormone-carrying proteins.
Skin (transdermal) route: Estrogen applied as a patch, gel or spray is absorbed through the skin and enters the blood without passing through the liver. It does not stimulate clotting proteins or blood fats. A steadier estrogen level can be achieved with lower amounts through the day.
Vaginal (local) route: Given as a cream, vaginal tablet or ring. The effect is limited to the vagina, the base of the bladder and the urinary tract. At the recommended use very little reaches the blood, and the blood estrogen level does not rise above the usual postmenopausal range.
Where Does the Difference Between Pill and Skin Route Show Up?
The sources highlight the difference in these areas:
- Blood clots (deep vein thrombosis, pulmonary embolism): Estrogen in pill form raises clot risk because it increases clotting protein production in the liver. In large observational studies, estrogen given through the skin has not been reported to increase this risk.
- Stroke: Estrogen in pill form is associated with a small to moderate increase in stroke risk. No such increase has been reported for low and standard amounts of estrogen given through the skin.
- Gallbladder: The pill form can increase the risk of gallstones and gallbladder inflammation; this increase is not expected with the skin route.
- Blood fats: The pill can raise triglyceride levels, so the skin route comes forward in women with high blood fats.
None of these differences is a warning against hormone therapy itself. The aim is to choose the route that suits the person's risk profile.
Which Route Is Preferred for Whom?
The skin route (patch, gel, spray) usually comes forward for:
- Women who are overweight or have metabolic syndrome (a combination of high sugar, blood pressure and blood fats)
- Smokers
- Women with high triglycerides or a chronic liver problem
- Women who have had a clot before or who carry vascular risk factors such as high blood pressure
- Women with poor absorption from the gut or difficulty swallowing pills
- Women starting late (after age 60 or more than 10 years after menopause). See our timing window article for details.
The pill route may be preferred for:
- Young, healthy women with no particular vascular, metabolic or clot risk factor
- Women who develop skin allergy, severe itching or a rash from patch adhesive
- Women who simply find a daily pill more convenient
The vaginal route is the first step for:
- Women who have no hot flashes or night sweats and only symptoms such as vaginal dryness, pain during intercourse, burning on urination or frequent urinary tract infections. This picture is called genitourinary syndrome of menopause.
Does Vaginal Treatment Replace Systemic Treatment?
No. Systemic treatment (pill, patch, gel, spray) spreads through the blood to the whole body; it relieves hot flashes, night sweats, sleep problems and mood swings, and protects bone density to reduce fracture risk. Vaginal local treatment has no protective effect on hot flashes or bone loss. It targets only local symptoms.
Local treatment does have one important advantage: at the recommended use it does not thicken the lining of the uterus, so a protective hormone (progestogen) usually does not need to be added. If systemic treatment is not enough for a woman who has both hot flashes and vaginal symptoms, the two can also be used together; this decision is made with the physician.
Why Does a Woman With a Uterus Need a Second Hormone?
In a woman whose uterus has not been removed, estrogen alone given systemically stimulates the lining of the uterus (endometrium) continuously. This increases the risk of excessive thickening of the lining and, over time, endometrial cancer. This is why progesterone or a similar protective hormone (progestogen) is added to estrogen in every woman with a uterus. The progestogen directs the lining to shed regularly or to thin out. It is usually not needed in women who have had the uterus removed.
The protective hormone can be given by different routes:
- By mouth: Natural progesterone, which is structurally identical to the body's own hormone, is among the first choices in terms of breast tissue and vascular safety.
- Vaginally: It can provide protection by reaching a high level in the uterus in women who feel drowsy or have mood swings with the oral form.
- With an intrauterine system: A progestogen-releasing intrauterine system delivers the hormone directly in the uterus, and the amount entering general circulation is small.
There are two regimens:
- Sequential (cyclic) regimen: Estrogen is given every day and the progestogen is added for 10-14 days of the month. A period-like bleed follows when the progestogen ends. This is usually preferred in perimenopause or the first years of menopause.
- Continuous combined regimen: Both are taken together every day; the aim is a bleed-free course. It is usually used in women who are 1-2 years past their last period.
For information on natural (bioidentical) options see our bioidentical hormone therapy page.
What Is Done Before and After Starting?
- Before starting: A detailed history is taken, blood pressure is measured, and breast imaging (mammography) and a pelvic ultrasound showing the thickness of the uterine lining are reviewed. For the breast cancer question see hormone therapy and breast cancer.
- After starting: The first check is about 3 months later. After that, at least once a year, symptoms, side effects, blood pressure, breast health and any unexpected vaginal bleeding are reviewed. For a general look at safety, read is hormone therapy safe.
Frequently Asked Questions
Are patches or gels as effective as pills?
Estrogen given through the skin is also effective for hot flashes and night sweats. The difference is that it bypasses the liver and gives a steady level with lower amounts. The route is chosen by looking at symptoms, risk profile and personal preference together.
What if the patch does not stick or the skin turns red?
If itching or a rash develops from the adhesive, another skin option such as a gel or spray, or the pill route, can be considered. It is better to discuss it with your physician than to change it on your own.
Do I need a protective hormone while using vaginal estrogen?
At the recommended local use, thickening of the uterine lining is not expected, so it is usually not needed. If use becomes long or bleeding occurs, the physician reassesses.
Is it right to say the pill is bad and the skin route is good?
No. In young, healthy women without any risk factors, the pill can also be a suitable option. What matters is choosing the route according to the person's vascular, metabolic and clot risk and reviewing it with regular check-ups.
Does the choice of route depend on lifestyle?
Yes. Smoking, excess weight, high blood pressure and high blood fats can bring the skin route forward. All of these are assessed together at the examination.